Maze Therapeutics’ Growth Requires a Strategy Expert

Maze, dedicated to translating genetic insights into precision medicines for rare diseases, has been building an impressive portfolio of potential therapy candidates due to its proprietary COMPASS platform. Using human genetic data, the technology is mapping novel connections between known genes and their influence on disease progression. To keep up with their growth, the company tapped pharma business leader Atul Dandekar as Chief Strategy Officer.

Dandekar brings more than 25 years of experience leading strategy, operations, clinical development, and commercialization for biotech and pharmaceutical companies. He hails from Genentech and Roche, where he served as Vice President, Global Franchise Head for Ophthalmology. With his past experience leading global development and strategy, he will help advance the precision therapies to clinical development. Dandekar commented, “With our ability to elucidate precision medicines based on novel genetic insights, we have a significant opportunity to shift the future of how specific individuals are treated for their disease.”

New Head of R&D at Gilead

Former Amgen exec, Flavius Martin, MD has been named as Gilead’s new Executive Vice President, Research. Dr Martin is taking over from 30-year veteran Bill Lee, PhD. At Amgen, Dr. Martin was VP of Research Biology, contributing to discoveries in oncology, inflammation, and cardiometabolic research. He will now lead Gilead in its renewed focus on virology, following the emergency approval of its repurposed Ebola drug remdesivir, the first drug to be authorized against COVID-19.

“Flavius brings decades of experience in early drug discovery research and identification of promising therapeutic candidates,” commented Gilead’s Chairman and CEO Daniel O’Day. “He has deep scientific expertise across therapeutic areas and has led the creation of high-quality portfolios in prior roles. I am delighted to welcome him to Gilead as we continue to expand and diversify our portfolio of new medicines.”

Business Council for Peace (Bpeace)

BPeace is a non-profit working in crisis-affected communities to empower women in business. Sabrina Prince, Executive Vice President of FCB Health Europe, has taken up a Board of Directors position. With her 20+ years of health marketing experience, she advises hospitality, healthcare, and consumer brands to help them grow and build customer loyalty.

Deep 6 AI

The AI company focused on accelerating patient recruitment for clinical trials announced Jason Attanucci has joined the company as Vice President of Life Sciences. In this new role, Attanucci will introduce the Deep 6 AI Clinical Trials Acceleration Software (CTAS) to the life sciences eClinical market. He is charged with bringing the software platform to biopharmaceutical sponsors and contract research organizations around the world.

Frequency Therapeutics

Kevin Franck, PhD, a well-known leader in hearing healthcare, has joined Frequency as Senior Vice President of Strategic Marketing and New Product Planning. A licensed audiologist, Dr. Franck has 25 years of experience in the development and commercialization of medical devices for people with hearing loss. He will lead the biopharma company on its ambitious quest to repair the underlying damage that is the primary cause of acquired hearing loss.

GSW

The Syneos Health advertising agency grows its team along with its West Coast reach. Twelve-year GSW veteran, Scott Page becomes the new Group Managing Director of GSW-West Coast to develop innovative brand-building strategies and results-generating communications, focusing on brands that require a high level of dialogue between HCPs and patients. He brings deep knowledge of healthcare advertising, medical communications, and sales experience to the role. Carolyn Gargano is the newly hired SVP Creative Director, charged with leading agency-wide initiatives that champion creativity, with an added focus on social purpose campaigns that make our world a healthier place. Rob Roth comes to GSW as SVP Account Director from The Bloc with an impressive record of big-name brand marketing for products such as Vyvanse, Eylea, Xarelto, and more.

Medable

Medable, provider of a leading cloud platform for patient-centered drug development, hires human-centered design guru Sina Mossayeb as Chief Design Officer. Mossayeb will be bringing human-centered design to products and processes, focusing on improving clinical trial experiences by advising customers on innovative ways to make trials less burdensome and more patient focused. Coming from award-winning design company IDEO, he will transform the clinical trial experience for patients regardless of geography, income, and race.

ReForm Biologics

Ex-Genzyme exec Jim Sherblom has joined the biopharma company as Chairman of its Board of Directors to lead a new strategy. ReForm is now aiming to convert intravenous formulations that need to be given in hospitals to subcutaneous injections that can be given in outpatient settings, which will help to improve treatment adherence with more convenient and flexible formulations. Sherblom will take on the many challenges and needed adaptations that this shift in strategy presents.

Relevate Health Group and Arteric

The leaders in healthcare provider marketing via machine learning and data appointed new members to their Board of Directors, including Michael Darviche and Cynthia Schwalm. Darviche is a technology, digital, and data expert who has been an executive lead on company transformations throughout his career. His current firm, Bridge22, helps high-growth companies in product, marketing, and M&A. Schwalm is a seasoned executive with extensive experience developing and expanding healthcare organizations in the pharmaceutical, startup, and biotech industries. Schwalm held senior leadership positions at Johnson & Johnson, Amgen, and other global big-name companies.

Syneos Health Communications

The healthcare agency collective has expanded its creative team with the addition of Orrin Pollard, Director of European Creative Expression, and Christina Pantelias, EVP of Strategy, GSW New York. Pollard was the founder and creative director of DDB Remedy UK and has led creative teams and global campaigns across every therapeutic area for 25 years. Pantelias is a well-known brand builder who focuses on connecting people with brands and putting together high-performing teams. The new talent will work across Syneos Health Communications to provide a clear, definitive, and persuasive voice to accelerate research and innovation to improve the health and well-being of society. They will work in scalable, purpose-built teams that partner across disciplines and geographies to accelerate brand performance.

Ads

You May Also Like

The Online Reputation of Cymbalta

Last month, we started our series on the online reputations of the top 10 ...

2020 Pharma Choice Social Media Gold Winner JPA Health and Medicines360

JPA Health and Medicines360 Birth Control is #NotAwkward We launched an unbranded social media ...

Healthcare Watch March 2020

Brand Beat: Sony to Market Operating Room System in U.S. The FDA has given ...